Status:
WITHDRAWN
Dose Intralipid Infusion Reduces Pregnancy Complications Caused by Antiphospholipid Antibody Syndrome?
Lead Sponsor:
Tanta University
Conditions:
Antiphospholipid Syndrome in Pregnancy
Eligibility:
FEMALE
20-40 years
Phase:
PHASE4
Brief Summary
This study will address the value of adding intralipid infusion in reducing pregnancy complications related to antiphospholipid syndrome
Detailed Description
This study will be conducted in the Department of Obstetrics and Gynecology, Tanta University on patients attending the antenatal care clinic and also on patients attending the researchers private cli...
Eligibility Criteria
Inclusion
- Pregnant women at booking date who were already diagnosed to have antiphospholipid syndrome (APS) .
Exclusion
- Patients with gestational age ≥ 9 weeks
- patients with diagnosed other auto-immune disorder
- patients with chronic hypertension, diabetes mellitus, thyroid disorders,
- patient with renal diseases
- patients who requested to withdraw from the study at any point .
Key Trial Info
Start Date :
April 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 31 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04274803
Start Date
April 1 2020
End Date
May 31 2021
Last Update
June 14 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Adel Elgergawy
Tanta, Egypt, 3111